BTAI
Price
$0.39
Change
-$0.02 (-4.88%)
Updated
Dec 17, 04:59 PM (EDT)
78 days until earnings call
PMCB
Price
$1.65
Change
-$0.02 (-1.20%)
Updated
Dec 18, 10:30 AM (EDT)
Earnings call today
Ad is loading...

BTAI vs PMCB

Header iconBTAI vs PMCB Comparison
Open Charts BTAI vs PMCBBanner chart's image
BioXcel Therapeutics
Price$0.39
Change-$0.02 (-4.88%)
Volume$100
CapitalizationN/A
PharmaCyte Biotech
Price$1.65
Change-$0.02 (-1.20%)
Volume$114
CapitalizationN/A
BTAI vs PMCB Comparison Chart
Loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BTAI vs. PMCB commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a Hold and PMCB is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (BTAI: $0.39 vs. PMCB: $1.67)
Brand notoriety: BTAI and PMCB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 84% vs. PMCB: 13%
Market capitalization -- BTAI: $18.86M vs. PMCB: $11.64M
BTAI [@Biotechnology] is valued at $18.86M. PMCB’s [@Biotechnology] market capitalization is $11.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whilePMCB’s FA Score has 1 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • PMCB’s FA Score: 1 green, 4 red.
According to our system of comparison, PMCB is a better buy in the long-term than BTAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 5 TA indicator(s) are bullish while PMCB’s TA Score has 5 bullish TA indicator(s).

  • BTAI’s TA Score: 5 bullish, 5 bearish.
  • PMCB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PMCB is a better buy in the short-term than BTAI.

Price Growth

BTAI (@Biotechnology) experienced а -11.22% price change this week, while PMCB (@Biotechnology) price change was +3.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.45%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

BTAI is expected to report earnings on Mar 06, 2025.

PMCB is expected to report earnings on Dec 18, 2024.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BTAI($18.9M) has a higher market cap than PMCB($11.6M). PMCB YTD gains are higher at: -22.685 vs. BTAI (-86.776). PMCB has higher annual earnings (EBITDA): -4.12M vs. BTAI (-56.15M). PMCB has more cash in the bank: 86.9M vs. BTAI (40.4M). PMCB has less debt than BTAI: PMCB (75.2K) vs BTAI (105M). BTAI has higher revenues than PMCB: BTAI (2.28M) vs PMCB (0).
BTAIPMCBBTAI / PMCB
Capitalization18.9M11.6M163%
EBITDA-56.15M-4.12M1,364%
Gain YTD-86.776-22.685383%
P/E RatioN/A1.90-
Revenue2.28M0-
Total Cash40.4M86.9M46%
Total Debt105M75.2K139,628%
FUNDAMENTALS RATINGS
BTAI vs PMCB: Fundamental Ratings
BTAI
PMCB
OUTLOOK RATING
1..100
5313
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
9562
P/E GROWTH RATING
1..100
10085
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PMCB's Valuation (15) in the null industry is significantly better than the same rating for BTAI (82) in the Biotechnology industry. This means that PMCB’s stock grew significantly faster than BTAI’s over the last 12 months.

PMCB's Profit vs Risk Rating (100) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that PMCB’s stock grew similarly to BTAI’s over the last 12 months.

PMCB's SMR Rating (95) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that PMCB’s stock grew similarly to BTAI’s over the last 12 months.

PMCB's Price Growth Rating (62) in the null industry is somewhat better than the same rating for BTAI (95) in the Biotechnology industry. This means that PMCB’s stock grew somewhat faster than BTAI’s over the last 12 months.

PMCB's P/E Growth Rating (85) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that PMCB’s stock grew similarly to BTAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BTAIPMCB
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NSA41.150.01
+0.02%
National Storage Affiliates Trust
TUSK2.88-0.04
-1.37%
Mammoth Energy Services
GGG86.21-1.22
-1.40%
Graco
RDFN8.79-0.30
-3.30%
Redfin Corp
INDP0.91-0.05
-5.31%
Indaptus Therapeutics

BTAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BTAI has been loosely correlated with ORMP. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BTAI jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BTAI
1D Price
Change %
BTAI100%
-4.01%
ORMP - BTAI
44%
Loosely correlated
-1.67%
SYBX - BTAI
42%
Loosely correlated
-2.36%
AXON - BTAI
42%
Loosely correlated
-2.09%
INO - BTAI
39%
Loosely correlated
-8.84%
IGMS - BTAI
38%
Loosely correlated
+1.08%
More

PMCB and

Correlation & Price change

A.I.dvisor tells us that PMCB and FATE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PMCB and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMCB
1D Price
Change %
PMCB100%
-1.18%
FATE - PMCB
33%
Poorly correlated
-6.00%
MBRX - PMCB
28%
Poorly correlated
-15.07%
BTAI - PMCB
28%
Poorly correlated
-4.01%
DTIL - PMCB
28%
Poorly correlated
-3.38%
ELVN - PMCB
27%
Poorly correlated
+3.48%
More